Current possibilities of influencing the main cardiovascular risk factors in patients with type 2 diabetes mellitus
Background. Cardiovascular morbidity increases notably among patients with diabetes. A correlation between leptin resistance and cardiovascular risk was found in patients with arterial hypertension and metabolic syndrome. However, there are no data about the influence of empagliflozin on leptin leve...
Main Authors: | O.Ya. Kobrynska, O.M. Didushko |
---|---|
Format: | Article |
Language: | English |
Published: |
Zaslavsky O.Yu.
2022-12-01
|
Series: | Mìžnarodnij Endokrinologìčnij Žurnal |
Subjects: | |
Online Access: | https://iej.zaslavsky.com.ua/index.php/journal/article/view/1220 |
Similar Items
-
Cardiovascular death risk reduction in type 2 diabetes patients with confirmed cardiovascular diseases
by: Е. V. Shlyakhto, et al.
Published: (2018-09-01) -
Associations of concurrent early‐life famine exposure and adulthood obesity with type 2 diabetes mellitus in middle‐aged Chinese
by: Qian Yi, et al.
Published: (2024-02-01) -
Comparison of empagliflozin and vildagliptin for efficacy and safety in type 2 diabetes mellitus in the Pakistani population
by: Asima Khan, et al.
Published: (2022-08-01) -
Clinical Study of Metabolic Parameters, Leptin and the SGLT2 Inhibitor Empagliflozin among Patients with Obesity and Type 2 Diabetes
by: Zsolt Szekeres, et al.
Published: (2023-02-01) -
A NEW INDICATION FOR EMPAGLIFLOZIN: TURNING POINT IN THE TREATMENT OF TYPE 2 DIABETES
by: M. V. Amosova, et al.
Published: (2017-12-01)